RxDoctor Payments Data

Robert Rogers, MD

Interventional Cardiology · Aurora, CONPI 1952506107

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Medtronic at 32.9% of the total. Reporting peaked in 2019 at $162 and has fallen 90.4% since, to $16 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CO, where the typical reported total is $6,820.

$358in general payments, 2019–2025

Across 11 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$118
  • Abiomed$103
  • Philips North America LLC$71
  • Cardiovascular Systems Inc.$39
  • Stryker$16
  • Regeneron Healthcare Solutions, Inc.$11
$223,833in research payments, 2019–2025

Across 16 payments — averaging $13,990 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$221K
  • Philips North America LLC$2K

What the payments were for

  • Food & beverage$358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$358 in reported general payments places this provider in the 5th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$87,220
Medicare patients
229
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$44,619
XareltoRivaroxaban12$13,346
Ezetimibe30$1,167
Rosuvastatin Calcium26$690
Atorvastatin Calcium46$516
Metoprolol Succinate35$499
Losartan Potassium29$273
Spironolactone20$245
Amlodipine Besylate26$238
Metoprolol Tartrate12$190
ClopidogrelClopidogrel Bisulfate29$186

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →